Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Tang Capital Management LLC

Tang Capital Management LLC increased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 225.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,900,000 shares of the company's stock after buying an additional 4,087,005 shares during the quarter. Tang Capital Management LLC owned 4.29% of Compass Therapeutics worth $8,555,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC raised its position in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company's stock worth $314,000 after purchasing an additional 112,614 shares during the last quarter. SG Americas Securities LLC increased its stake in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after buying an additional 356,352 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after purchasing an additional 11,326 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Compass Therapeutics by 25.2% in the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock valued at $404,000 after purchasing an additional 56,000 shares during the period. Finally, Bleakley Financial Group LLC raised its stake in Compass Therapeutics by 250.7% in the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock valued at $58,000 after acquiring an additional 28,589 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Stock Down 0.7%

Shares of NASDAQ CMPX traded down $0.02 during trading on Friday, reaching $2.09. 115,774 shares of the company traded hands, compared to its average volume of 916,033. Compass Therapeutics, Inc. has a 52-week low of $0.77 and a 52-week high of $4.08. The firm has a 50 day simple moving average of $1.91 and a 200-day simple moving average of $2.11. The stock has a market capitalization of $288.32 million, a PE ratio of -5.63 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12). As a group, research analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Insider Activity

In other news, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. This represents a 2,000.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Company insiders own 29.80% of the company's stock.

Analyst Upgrades and Downgrades

CMPX has been the subject of several recent research reports. Wedbush reiterated an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target for the company. D. Boral Capital reiterated a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th. Guggenheim reduced their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Compass Therapeutics currently has an average rating of "Buy" and an average target price of $13.13.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.